Immunotherapy of chronic hepatitis B by anti HBV vaccine

Acta Gastro-Enterologica Belgica

Volumn 61, Issue 2, 1998, Pages 228-233

  Pol, Stanislas ^a   Couillin, Isabelle ^a   Michel, Marie Louise ^a   Driss, Françoise ^b   Nalpas, Bertrand ^a   Carnot, Françoise ^c   Berthelot, Pierre ^a   Bréchot, Christian ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b BICÊTRE HOSPITAL   (France)

^c Hopital Laennec   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; LAMIVUDINE; VIDARABINE;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; DRUG EFFICACY; FOLLOW UP; HEPATITIS B; HUMAN; IMMUNOTHERAPY; INFECTION RISK; LIVER CARCINOMA; LIVER CIRRHOSIS; RISK FACTOR; VACCINATION; VIRUS REPLICATION;

ADULT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; TREATMENT OUTCOME;

EID: 0031866296     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. WRIGHT T.L., LAU J.Y.N. Clinical aspects of hepatitis B virus infection. Lancet, 1993, 342 : 1340-4
2. CHU C.M., KARAYIANNIS P., FOWLER M.J.F., MONJARDINO J., LIAW Y.F., THOMAS H.C. Natural history of chronic hepatitis B virus infection in Taiwan studies of hepatitis B virus DNA in serum Hepatology, 1985, 5 : 431-4.
3. DE FRANCHIS R., MEUCCI G., VECCHI M., TATARELLA M, COLOMBO M., DEL. NINNO E., RUMI M.G, DONATO M.F., RONCHI G The natural history of asymptomatic hepatitis B surface antigen carriers. Ann. Intern. Med., 1993, 118 : 191-4
4. COLOMBO M. Hepatocellular carcinoma J Hepatol, 1992, 15 : 225-36.
5. TSUKUMA H, HIYAMA T., TANAKA S., NAKAO M., YABUUCHI T, KITAMURA T., NAKANISHI K., FUJIMOTO I., INOUE A , YAMAZAKI I, KAWASHIMA T. Risks factors for hepatocellular carcinoma among patients with chronic liver disease. N. Engl. J. Med , 1993, 328 : 1797-801.
6. BROOK M.G., KARAYIANNIS P., THOMAS H C Which patients with chronic hepatitis B virus infection will respond to alpha interferon therapy ? a statistical analysis of predictive factors. Hepatology, 1989, 10 : 761-3.
7. PERRILLO R.P, REGENSTEIN F.G, PETERS M.G., DESCHRYVER-KECSKEMETI K., BODICKY C.J., CAMPBELL C.R., KUHNS M.C Prednisone withdrawal followed by recombinant alpha-Interferon in the treatment of chronic type B hepatitis. A randomized controlled trial. Ann Intern Med., 1988, 109 : 95-100.
8. WONG D K H, CHEUNG A.M., O'ROURKE K., NAYLOR C.D., DETSKY A.S., HEATHCOTE J. Effect of alpha-interferon in patients with hepatitis B e antigen-positive chronic hepatitis B , a meta-analysis. Ann Intern Med , 1993, 119 : 312-23.
9. ALEXANDER G.J.M., BRAHM J., FAGAN E.A., SMITH H M., DANIELS H.M., EDDEI STON A.L W., WILLIAMS R Loss of HBsAg with Interferon therapy in chronic hepatitis B virus infection. Lancet, 1987, ii : 66-9.
10. KORENMAN J., BAKER B., WAGGONER J., EVERHART J E., DI BISCEGLIE A M., HOOFNAGLE J H. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann. Intern. Med., 1991, 114 629-34.
11. MARTIN J., BOSCH O, MORALEDA G., BARTOLOME J., QUIROGA J.A, CARRENO V Pilot study of recombinant human granulocyte-macrophage colony stimulating factor in the treatment of chronic hepatitis B. Hepatology, 1993, 18 : 775-80.
12. MUTCHNICK M G, APPELMAN H.D., CHUNG H T, ARAGONA F., GUPTA T.P., CUMMINGS G.D., WAGGONER J G., HOFFNAGLE J.H., SHAFRITZ D.A. Thymosin treatment of chronic hepatitis B : a placebo-controlled pilot trial. Hepatology, 1991, 14 : 409-15
13. ILAN Y, NAGLER A., ADLER R, NAPARSTEK E., OR R , SLAVIN S., BRAUTBAR C., SHOUVAL D. Adoptive transfer of immunity to hepatitis B virus after T-cell depleted allogeneic bone marrow transplantation. Hepatology, 1993, 18 : 246-52.
14. POL S., DRISS F., CARNOT F , MICHEL M-L., BERTHELOT P., BRECHOT C Vaccination against hepatitis B virus : an efficient immunotherapy against hepatitis B multiplication C R. Acad. Sci. Paris, 1993, 316 : 688-91.
15. BURKE D.S Vaccine therapy for HIV : a historical review of the treatment of infectious diseases by active specific immunization with microbe-derived antigens. Vaccine, 1993, 11 : 883-91
16. COHEN J. Vaccines get a new twist. Science, 1994, 264 503-5.
17. COPE Z. Almroth Wright, founder of modern vaccine-therapy. Thomas Nelson and Sons, Ltd., London, 1966
18. STRAUSS S E., COREY L., BURKE R.L., SAVARESE B., BARMUM G., KRAUSE P R., KOST R.G, MEIER J.L., SEKULOVICH R., ADAIR, DEKKER C.L. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes Lancet, 1994, 343 : 1460-3.
19. STANFORD J.L. The history and the future of vaccination and immunotherapy for leprosy Trop. Geo. Med., 1994, 46 : 109-13.
20. CONVIT J , ULRICH M., FERNANDEZ C.T., TAPIA F.J , CACERESDITTMAR G., CASTES M., RONDON A.J. The clinical and immunological spectrum of american cutaneous leishmaniasis. Trans R. Trop. Med. Hyg., 1993, 87 : 444-8.
21. REDFIFLD R.R., BIRX D.L. KETTER N , TRAMONT E., POLONIS V., DAVIS C., BRUNDAGE J.F, SMITH G., JOHNSON S., FOWLER A., WIERZBA T., SHAFFERMAN A., VOLVOVITZ F., OSTER C , BURKE D A phase I evaluation of the safety and immunogenicity of immunization with recombinant gp 160 in patients with early human immunodeficiency virus infection N. Engl J Med., 1991, 321 : 1621-6
22. ZAGURY D , LEONARD R , FOUCHARD M., REVEIL B., BERNARD J., ITTELE D., CATLAN A., ZIRIMVABAGADO I , KALUMBU M., JUSTIN W. Immunization against AIDS in humans (letter). Nature, 1987, 326 249-50.
23. STANBERRY L. R , BERNSTEIN D.I., BURKE R.L., PACHL C , MYERS M G Vaccination with recombinant herpex simplex virus glycoproteins . protection against initial and recurrent genital herpes. J. Infect. Dis , 1987, 155 : 914-20.
24. REDFIELD R R, BIRX D.L. HIV-specific vaccine therapy . concepts, status and future directions. Aids Research and Human Retroviruses, 1992, 8 : 1051-8
25. BALLARDINI G , GROFF P., PONTISSO P., GIOSTRA F., FRANCESCONI R., LENZI M. et al Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A, B. C and Intercellular adhesion-1 molecules : clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C. J. Clin. Invest., 1995, 95 : 2067-75.
26. SYLVAN S.P.E, HELLSTROM U.B, LUNDBERGH P.R, Detection of cellular and humoral immunity to hepatitis B surface antigen (HsAg) in asymptomatic HBsAg carriers. Clin Exp. Immunol., 1985, 62 : 288-95
27. DUSHEIKO G M, HOOFNAGLE J H, COOKSLEY W.G , JAMES S P, JONES A. Synthesis of antibodies to hepatitis B virus by cultured lymphocytes from chronic hepatitis B surface antigen carriers. J. Clin Invest , 1983, 71 : 1104-113
28. MANCINI M., HADCHOUEL. M., TIOLLAIS P., POURCEL C., MICHEL M-L Induction of anti-hepatitis B surface antigen (HBsAg). Antibodies in HBsAg producing transgenic mice : a possible way of circumventing "nonresponse" to HBsAg J. Med. Virol , 1993, 39 : 67-74.
29. AKBAR S.M.F., KUROSA K., TANIMOTO K., MASUMOTO M , MICHITAKA K , HORIIKE N., ONJI M. Vaccine therapy for hepatitis B virus (HBV)-carriers . a study in murine HBV-carriers on dose, duration and prognosis. Hepatology, 1995, 22 224 A (Abstract)
30. MILICH D.R , MC LACHLAN A., CHISARI F.V , KENT S.B.H., THORNTON G.B Immune response to the pre-S1 region of the hepatitis B surface antigen HBsAg : a pre-S1 specific T cell response can bypass nonresponsiveness to the pre-S2 and S regions of HBsAg. J Immunol., 1986, 137 : 315-22.
31. MILICH D.R., JONES J.F., HUGHES J L., PRICE J., RANEY A K et al. Is a function of the secreted hepatitis Be antigen to induce immunologie tolerance in utero? Proc. Natl. Acad. Sci. USA, 1990, 87 : 6599-603.
32. DIENSTAG J.L., STEVENS C.E., BHAN A.K , SZMUNESS W. Hepatitis B vaccine administered to chronic carriers of hepatitis B surface antigen. Ann. Intern Med., 1982, 96 : 575-9
33. POL S., DRISS F., MICHEL M.-L , NALPAS B., BERTHELOT P, BRÉCHOT C Specific vaccine therapy in chronic hepatitis B infection Lancet, 1994, 342 (Letter).
34. WEN Y.-M , WU X.-H., HU D.-C., ZHANG Q-P., GNO S.-Q. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet, 1995, 345 : 1575-1576 (Letter).
35. CARMAN W.F , KORULA J., WALLACE, MAC PHEE R., MIMMS L, DECKER. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet, 1995, 345 : 1406-7.